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Best medical practice should be informed 
by research evidence. However, translating 
study findings into clinical decisions is not 
straightforward. Ratio measures of effect 
such as the risk ratio are most commonly 
reported, but tell us little about absolute 
effects. For example, taking a statin reduces 
your risk of vascular events by about 20% a 
year across a wide range of baseline vascular 
risk.1 If your initial 10-year risk of such an 
event was 1% then taking a statin would 
reduce this risk by 0.2%, whereas if your 
initial risk was 20%, the reduction would 
be 4%. This shows how the absolute risk 
difference can be more clinically informative.
The number needed to treat (NNT) statistic 
was introduced over 30 years ago and has 
gained popularity as a useful measure to help 
clinicians understand research findings.2 
Abstract probabilities are converted into a 
more tangible quantity: number of patients 
treated. In the above statins example, the 
NNT for 10 years to avert one vascular event 
would be 500 among the low-risk group, but 
25 in the high-risk group.
NNT might appear to be an attractive 
measure to the busy clinician wishing to 
condense the results of a study into a single 
summary figure, but relying on it in isolation 
can be misleading. It is often given a concrete 
interpretation: ‘50 patients need to be treated 
to prevent one adverse outcome’. This is 
incomplete. A more accurate interpretation 
would be ‘if 50 patients with a similar risk 
to the study population were treated for the 
same time as the study population then, on 
average, one fewer would experience an 
adverse outcome compared with 50 patients 
treated in the same way as the study control 
population during the study period’.
This might seem slightly fastidious but the 
differences are crucial.
NNT IS ONLY A STATISTIC
The language of NNT strongly suggests 
cause and effect: for every 50 people I treat 
one will be saved from harm. This might be 
appropriate if the treatment effect is derived 
from large, well-conducted randomised 
controlled trials but could be a dangerous 
assumption for many studies.
NNT DEPENDS ON THE STUDY CONTEXT
NNT is specific to not only a single treatment, 
but also a specific study population and time 
frame. The NNT for statin treatment was 
500 for the low-risk patient in the example 
above but 25 for the high-risk patient per 
year, and lower still for longer treatment 
periods. Therefore, to apply an NNT to your 
patient the first question should be, ‘How 
similar is my patient to the patients in the 
study?’ This is especially important when 
NNTs for different alternative treatments 
are compared. If the study populations have 
different baseline risks, then the NNTs 
cannot be compared. Similarly, care must 
be taken in generating NNTs from meta-
analyses where the individual studies might 
have very different baseline risks.
NNT IS AN AVERAGE ASSOCIATED WITH 
UNCERTAINTY
NNT might sound like a concrete number but 
in fact it is an average measure that, like all 
statistics, is associated with uncertainty. We 
should therefore expect it to be quoted along 
with a measure of its uncertainty. Usually, 
this is expressed in terms of a confidence 
interval (CI); this is a plausible range of values 
given the study findings. Although CIs can be 
generated for the NNT, they can be confusing 
because an ineffective treatment will have an 
NNT of infinity.
For example, 6% (95% CI = –3% to 15%) 
more people reported a good recovery 
from ankle sprain at 3 months after 
receiving physiotherapy and this absolute 
risk difference translates to an NNT of 16.7 
(number needed to treat to harm [NNTH] 
33.3 to ∞ to number needed to treat to benefit 
[NNTB] 6.7).3 The CI for the absolute risk 
difference is fairly intuitive: physiotherapy 
might improve recovery in as many as 15% 
or might worsen it up to 3%. However, the CI 
for the NNT is trickier: physiotherapy might 
improve recovery in as few as 6.7 patients or 
worsen recovery in as few as 33.3 patients.
IS NNT BETTER THAN THE 
ALTERNATIVES?
There is evidence that lay people have trouble 
interpreting NNT and an alternative should 
be used in this context.4 Among doctors, 
studies have not demonstrated that NNT 
is any better understood than absolute risk 
reductions.5
The supposed benefit of NNT, that it 
expresses a probability in terms of a number 
of patients, can easily be applied directly to 
the absolute risk difference. For example, 
an absolute risk reduction of 5% could be 
expressed as ‘five fewer adverse outcomes 
per 100 people treated’. This also reminds 
the reader that we have not been told the 
baseline risk: ‘five fewer than what?’
Ultimately, deciding which statistic is most 
easily understood is highly subjective and 
any measure that improves understanding is 
valuable. NNTs can be one useful measure, 
but some caution is needed, especially 
around the strength of evidence underlying 
them.
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